INFI Infinity Pharmaceuticals Inc

Price (delayed)

$2.3

Market cap

$203.89M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$98.45M

Highlights
Infinity Pharmaceuticals's quick ratio has surged by 88% YoY
The company's gross profit rose by 32% YoY and by 2.3% QoQ

Key stats

What are the main financial stats of INFI
Market
Shares outstanding
88.65M
Market cap
$203.89M
Enterprise value
$98.45M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.92
Price to sales (P/S)
99.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.97
Earnings
Revenue
$1.76M
EBIT
-$39.32M
EBITDA
-$38.84M
Free cash flow
-$37.46M
Per share
EPS
-$0.64
Free cash flow per share
-$0.49
Book value per share
$0.59
Revenue per share
$0.02
TBVPS
$1.48
Balance sheet
Total assets
$112.4M
Total liabilities
$60.35M
Debt
$1.31M
Equity
$52.05M
Working capital
$99.85M
Liquidity
Debt to equity
0.03
Current ratio
11.56
Quick ratio
11.29
Net debt/EBITDA
2.72
Margins
EBITDA margin
-2,207.8%
Gross margin
100%
Net margin
-2,344.2%
Operating margin
-2,250.1%
Efficiency
Return on assets
-66.7%
Return on equity
-4,651.4%
Return on invested capital
-507.2%
Return on capital employed
-38.2%
Return on sales
-2,235.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INFI stock price

How has the Infinity Pharmaceuticals stock price performed over time
Intraday
-9.09%
1 week
-10.16%
1 month
-26.05%
1 year
170.59%
YTD
8.49%
QTD
-23.08%

Financial performance

How have Infinity Pharmaceuticals's revenue and profit performed over time
Revenue
$1.76M
Gross profit
$1.76M
Operating income
-$39.58M
Net income
-$41.24M
Gross margin
100%
Net margin
-2,344.2%
The company's gross profit rose by 32% YoY and by 2.3% QoQ
The revenue has grown by 32% year-on-year and by 2.3% since the previous quarter
INFI's net margin is up by 29% year-on-year
INFI's operating margin is up by 29% YoY

Growth

What is Infinity Pharmaceuticals's growth rate over time

Valuation

What is Infinity Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.92
P/S
99.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
55.97
Infinity Pharmaceuticals's EPS has increased by 17% YoY and by 6% QoQ
INFI's P/S is 35% above its last 4 quarters average of 73.4
The revenue has grown by 32% year-on-year and by 2.3% since the previous quarter

Efficiency

How efficient is Infinity Pharmaceuticals business performance
Infinity Pharmaceuticals's ROIC has plunged by 170% YoY and by 77% from the previous quarter
Infinity Pharmaceuticals's return on sales has increased by 28% YoY
INFI's return on assets is up by 21% since the previous quarter and by 12% year-on-year

Dividends

What is INFI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INFI.

Financial health

How did Infinity Pharmaceuticals financials performed over time
Infinity Pharmaceuticals's total assets is 86% more than its total liabilities
Infinity Pharmaceuticals's total assets has soared by 186% from the previous quarter and by 97% YoY
Infinity Pharmaceuticals's quick ratio has surged by 88% YoY
INFI's debt is 97% smaller than its equity
The debt to equity has soared by 150% from the previous quarter and by 104% YoY
INFI's debt is down by 27% year-on-year and by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.